Key result
Live-attenuated oral rotavirus vaccines demonstrate higher efficacy in high-income countries but greater impact in low-income countries, despite implementation setbacks in over 90 countries.
Why the study?
Despite vaccine efficacy, more than 90 countries have not implemented live-attenuated oral rotavirus vaccines due to cost, policy, strategic preventive measures, and infrastructure setbacks.
Live-attenuated oral rotavirus vaccines show higher efficacy in high-income countries but greater overall impact in low-income countries, though implementation remains a challenge globally.
No takes yet. Share an insight, caveat, or question.
Highlights greater public health benefit in low-income settings despite lower efficacy; leaves open optimization and implementation questions.
Folorunso et al. (2020) conducted a review in Rotavirus-associated infection. Live-attenuated oral rotavirus vaccines was evaluated. Live-attenuated oral rotavirus vaccines demonstrate higher efficacy in high-income countries but greater impact in low-income countries, despite implementation setbacks in over 90 countries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: